AtheroGenics is developing
small-molecule drugs for the treatment
of such chronic inflammatory diseases
as atherosclerosis (clogging of the
arteries), asthma, and rheumatoid
arthritis. The company's products
prevent the production of inflammatory
proteins; its lead product, AGI-1067, is in
trials as a treatment for restenosis (the
reclosure of arteries after angioplasty).
AtheroGenics has identified other
compounds that may be used to treat
cystic fibrosis and organ transplant
rejection. Schering-Plough is helping to
develop AGI-1067. Founded in 1993 by
Emory University scientist Russell
Medford, AtheroGenics' investors
include William Blair & Company,
Alliance Technology Ventures, and
Sprout Group.
8995 Westside Pkwy.
Alpharetta, GA
30004 (Map)
Phone: 678-336-2500
Fax: 678-336-2501
atherogenics.com
atherogenics.com
AtheroGenics is an emerging pharmaceutical
company
focused on the discovery, development and
commercialization of novel drugs for the
treatment
of chronic inflammatory diseases, such as
atherosclerosis, asthma, and arthritis. |
